New hope for AML patients: stronger chemo may work in Less-Fit adults
NCT ID NCT04195945
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This study tests whether giving full-strength chemotherapy (either CPX-351 or a combination called CLAG-M) can improve survival in adults with acute myeloid leukemia who are not healthy enough for standard intensive treatment. About 60 participants will be randomly assigned to one of the two drug regimens. The main goal is to see if either approach helps more patients live at least 3 months compared to using lower doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.